Driving the next generation of cell | 合法醫療器材資訊網

2021年2月24日 — We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, ... Read More

2021年5月12日 — Through its Life Sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to ... Read More

2020年5月20日 — Gaithersburg, MD, May 6, 2015 – MaxCyte® Inc., the pioneer in cell therapies using scalable, highperformance cell transfection systems, ... Read More

2020年5月20日 — The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an ... Read More

2020年5月20日 — With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. Read More

2021年1月7日 — Total of 12 announced clinical and commercial partnerships; ... Global partner of choice for non-viral cell engineering technology ... Read More

A Leading Provider of Cell-engineering Platform Technologies... · High-value life science markets sustain MaxCyte's strength · MaxCyte is the partner of choice ... Read More

This Presentation has been issued by MaxCyte Inc (the “Company”) a Company trading on ... Global partner of choice for non-viral cell engineering technology ... Read More

MaxCyte is the global leader in electroporation technology, the pre-eminent technology supporting non-viral cell and gene therapies, such as gene editing ... Read More

MaxCyte is a global, clinical-stage, cell-based therapy and life sciences company. As the inventors of the industry standard, non-viral cell-engineering ... Read More